DUBLIN, March 25, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/czqbv2/investigation) has announced the addition of the "Investigation Report on China Trastuzumab Market, 2009-2018" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Trastuzumab is a monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat certain breast cancers. Trastuzumab has a major impact in the treatment of HER2-positive metastatic breast cancers.
In China, less than 10% of women can get mammary diseases inspection every year for the limitation of medical conditions and lack of knowledge. Therefore, only 20% of breast cancers is detected at an early stage in China while 80% is detected at an early stage in the U.S.A.
The incidence of breast cancers ranks the first in malignant tumors. According to incomplete statistics, the incidence number of breast cancers exceeds 200,000 every year in China. By the end of 2013, the number of living breast cancer patients exceeded 500,000, above 1/3 of which were metastatic breast cancers. The incidence and mortality rates of breast cancers differ from urban to rural areas in China. In recent 10 years, the incidence of breast cancers in cities obviously increases but the mortality rate remains stable. However, the incidence and mortality rates of breast cancers in rural areas present obvious uprising trend. The number of breast cancer patients in cities is increasing, especially in young women groups. It is mainly caused by the change of lifestyle and diet habits and the incidence growth of other mammary diseases like fibroma. Take Fujian as an instance, from 1970s to the early 21 century, the mortality rate of breast cancers in Fujian presents an upward trend. The mortality rates in 1973-1975, 1990-1992 and 2004-2005 are separately 31.6/million, 34.2/million and 44.6/million. In 2011, the mortality rate of women breast cancer patients was 70.7/million in Fujian. Obviously, the mortality rate doubled during 2005-2011.
In China sample hospital market, the market share of trastuzumab is completely taken by Shanghai Roche and GENENTECH. During 2005-2013, the CAGR of market size of trastuzumab in sample hospitals exceeded 60%. The unit retail price maintains CNY 20,000 (USD 3,300) or more.
The patent of trastuzumab will expire in 2014. The huge profit margin and market potential attract many generic drug manufacturers. CRI sees many generic drugs will enter global market after 2015. According to CRI's investigation, many generic drug companies add trastuzumab to the R&D list, some of which has certain achievements.
Key Topics Covered:
1 Relevant Concepts of Trastuzumab
2 Market Overview of Trastuzumab in China, 2009-2013
3 Investigation on Sales Value of Trastuzumab in China, 2009-2013
4 Investigation on Market Share of Major Trastuzumab Manufacturers in China, 2009-2013
5 Investigation on Market Size of Trastuzumab by Dosage Form in China , 2009-2013
6 Reference Price of Trastuzumab in Hospital Market in China, 2013
7 Analysis on Major Trastuzumab Manufacturers in China, 2009-2013
8 Prospect of China Trastuzumab Market, 2014-2018
- GENENTECH (Subsidiary of Roche)
- Shanghai Roche Pharmaceuticals Ltd.
For more information visit http://www.researchandmarkets.com/research/czqbv2/investigation
Media Contact: Laura Wood , +353-1-481-1716, email@example.com
SOURCE Research and Markets